Second-line treatment

Second-line treatment

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Cancer Journey:
Cancer Type:
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC).
Cancer Journey:
Cancer Type:
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses if there is a role for PD-L1 testing after first line treatment.
Cancer Journey:
Cancer Type:
Disease Learning:
,
,
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Type:
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss second-line therapies for advanced NSCLC.
Cancer Journey:
Cancer Type:
Disease Learning:

Articles

Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
Cancer Journey:
Cancer Type:
In the span of a week, we’ve just had new FDA approvals of Keytruda (pembrolizumab) for previously treated advanced non-small cell lung cancer (NSCLC) patients with tumors that express PD-L1, followed by a broadened approval for Opdivo (nivolumab) for previously...
Cancer Journey:
Cancer Type:
It's been a big week for immunotherapy for lung cancer. Right on the heels of a press release that the PD-1 inhibitor Opdivo (nivolumab)...
Cancer Journey:
Cancer Type:
It was a big day for the lung cancer world. After seeing the tantalizing promise of immunotherapy for lung cancer over the past 3 years, but outside...
Cancer Journey:
Cancer Type:
It may not be the biggest present lung cancer patients could get for the holiday season, but the FDA just yesterday approved Cyramza (ramucirimab),...
Cancer Journey:
Cancer Type:

Community Forum

No Result Found